HSPA5 and acute myeloid leukemia: To test the efficacy of the GRP78-CAR T cells in vivo we first compared the antitumor activity of one IV dose of 3 × 106 GRP78.1x-, GRP78.2x- or GRP78.3x-CAR T cells in the AML MOLM13.GFP.ffluc NSG xenograft model (Fig. 5a–d).